Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

被引：0
|
作者：
T. Sakakida
T. Ishikawa
Y. Chihara
S. Harita
J. Uchino
Y. Tabuchi
S. Komori
J. Asai
T. Narukawa
A. Arai
H. Tsunezuka
T. Kosuga
H. Konishi
M. Moriguchi
H. Yasuda
F. Hongo
M. Inoue
S. Hirano
O. Ukimura
Y. Itoh
T. Taguchi
K. Takayama
机构：
[1] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology, Graduate School of Medical Science
[2] Kyoto Prefectural University of Medicine,Outpatient Oncology Unit, University Hospital
[3] Kyoto Prefectural University of Medicine,Department of Pulmonary Medicine, Graduate School of Medical Science
[4] Kyoto Prefectural University of Medicine,Department of Dermatology, Graduate School of Medical Science
[5] Kyoto Prefectural University of Medicine,Department of Urology, Graduate School of Medical Science
[6] Kyoto Prefectural University of Medicine,Department of Otolaryngology
[7] Kyoto Prefectural University of Medicine,Head and Neck Surgery, Graduate School of Medical Science
[8] Kyoto Prefectural University of Medicine,Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science
[9] Kyoto Prefectural University of Medicine,Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science
[10] Kyoto Prefectural University of Medicine,Division of Endocrine and Breast Surgery, Department of Surgery, Graduate School of Medical Science
来源：
Clinical and Translational Oncology | 2020年 / 22卷
关键词：
Immune-related adverse events; Programmed cell death 1 blockade; Immune checkpoint inhibitors; Antinuclear antibodies; Autoimmune diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 927
页数：8
相关论文
共 50 条
  • [21] Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies
    Yoneshima, Yasuto
    Tanaka, Kentaro
    Shiraishi, Yoshimasa
    Hata, Kojiro
    Watanabe, Hiroyuki
    Harada, Taishi
    Otsubo, Kohei
    Iwama, Eiji
    Inoue, Hiroyuki
    Masuda, Satohiro
    Nakanishi, Yoichi
    Okamoto, Isamu
    LUNG CANCER, 2019, 130 : 5 - 9
  • [22] Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
    Gong, Jun
    Le, Thang Q.
    Massarelli, Erminia
    Hendifar, Andrew E.
    Tuli, Richard
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [23] Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
    Pathak, Ranjan
    Pharaon, Rebecca R.
    Mohanty, Atish
    Villaflor, Victoria M.
    Salgia, Ravi
    Massarelli, Erminia
    CANCERS, 2020, 12 (12) : 1 - 13
  • [24] Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
    Elias, Rawad
    Giobbie-Hurder, Anita
    McCleary, Nadine Jackson
    Ott, Patrick
    Hodi, F. Stephen
    Rahma, Osama
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [25] Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study
    Storm, Bert N.
    Kalkhoran, Hanieh Abedian
    Wilms, Erik B.
    Brocken, Pepijn
    Codrington, Henk
    Houtsma, Danny
    Portielje, Johanneke E. A.
    de Glas, Nienke
    van der Ziel, Daisy
    van den Bos, Frederiek
    Visser, Loes E.
    JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (07) : 997 - 1002
  • [26] Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1
    Wang, Rui-na
    Yu, Qian
    Wang, Xiao-bo
    Zhu, Di
    Li, Guo-long
    Li, Zeng-xia
    Jiang, Wei
    Li, Wei
    Dang, Yong-jun
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (10) : 2103 - 2112
  • [27] Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1
    Rui-na Wang
    Qian Yu
    Xiao-bo Wang
    Di Zhu
    Guo-long Li
    Zeng-xia Li
    Wei Jiang
    Wei Li
    Yong-jun Dang
    Acta Pharmacologica Sinica, 2023, 44 : 2103 - 2112
  • [28] Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
    Pang, Kun
    Shi, Zhen-Duo
    Wei, Liu-Ya
    Dong, Yang
    Ma, Yu-Yang
    Wang, Wei
    Wang, Guang-Yue
    Cao, Ming-Yang
    Dong, Jia-Jun
    Chen, Yu-Ang
    Zhang, Peng
    Hao, Lin
    Xu, Hao
    Pan, Deng
    Chen, Zhe-Sheng
    Han, Cong-Hui
    DRUG RESISTANCE UPDATES, 2023, 66
  • [29] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Rosemarie Tremblay-LeMay
    Nasrin Rastgoo
    Hong Chang
    Journal of Hematology & Oncology, 11
  • [30] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Tremblay-LeMay, Rosemarie
    Rastgoo, Nasrin
    Chang, Hong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
12345